CA3137450A1 - Lipid nanoparticles - Google Patents
Lipid nanoparticles Download PDFInfo
- Publication number
- CA3137450A1 CA3137450A1 CA3137450A CA3137450A CA3137450A1 CA 3137450 A1 CA3137450 A1 CA 3137450A1 CA 3137450 A CA3137450 A CA 3137450A CA 3137450 A CA3137450 A CA 3137450A CA 3137450 A1 CA3137450 A1 CA 3137450A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- moiety
- nanoparticle
- peg
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839452P | 2019-04-26 | 2019-04-26 | |
| US62/839,452 | 2019-04-26 | ||
| US201962867098P | 2019-06-26 | 2019-06-26 | |
| US62/867,098 | 2019-06-26 | ||
| PCT/US2020/029907 WO2020219941A1 (en) | 2019-04-26 | 2020-04-24 | Lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3137450A1 true CA3137450A1 (en) | 2020-10-29 |
Family
ID=72941858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3137450A Pending CA3137450A1 (en) | 2019-04-26 | 2020-04-24 | Lipid nanoparticles |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168222A1 (OSRAM) |
| EP (1) | EP3959314A4 (OSRAM) |
| JP (1) | JP2022530018A (OSRAM) |
| CN (1) | CN114026233A (OSRAM) |
| AU (1) | AU2020262437A1 (OSRAM) |
| CA (1) | CA3137450A1 (OSRAM) |
| MA (1) | MA55766A (OSRAM) |
| WO (1) | WO2020219941A1 (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191315A1 (ru) * | 2018-11-09 | 2021-09-08 | Арбутус Биофарма Корпорэйшн | Катионные липиды, содержащие кремний |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| US12023376B1 (en) | 2020-04-17 | 2024-07-02 | Triad National Security, Llc | Conserved region T cell vaccines for coronavirus and methods of use |
| CN115768438A (zh) * | 2020-07-10 | 2023-03-07 | 盖纳万科学有限公司 | 用于向肺递送治疗剂的脂质纳米颗粒 |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| KR20230118715A (ko) | 2020-10-14 | 2023-08-11 | 조지 메이슨 리서치 파운데이션 인코포레이티드 | 이온화 가능 지질 및 이의 제조 및 사용 방법 |
| US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
| CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| CN117479963A (zh) * | 2020-12-18 | 2024-01-30 | 盖纳万科学有限公司 | Peg脂质和脂质纳米粒子 |
| WO2022198229A1 (en) * | 2021-03-17 | 2022-09-22 | Board Of Regents Of The University Of Nebraska | Lipid nanoparticle formulations and methods of use thereof |
| WO2022221736A2 (en) | 2021-04-16 | 2022-10-20 | Genentech, Inc. | Optimized tlr7 ligands and uses thereof |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN117940158A (zh) | 2021-09-03 | 2024-04-26 | 库瑞瓦格欧洲公司 | 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒 |
| EP4419677A4 (en) | 2021-10-18 | 2025-09-24 | Flagship Pioneering Innovations Vii Llc | DNA COMPOSITIONS AND RELATED METHODS |
| KR20230061895A (ko) * | 2021-10-29 | 2023-05-09 | 주식회사 아이큐어비앤피 | 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체 |
| CN117203186A (zh) * | 2022-05-13 | 2023-12-08 | 南方科技大学 | 一种含有二硫键的脂质化合物及其组合物 |
| WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
| EP4529472A1 (en) | 2022-05-23 | 2025-04-02 | Logicbio Therapeutics, Inc. | Gene therapy compositions and methods of use thereof |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
| CN119562807A (zh) | 2022-05-30 | 2025-03-04 | 生物技术公司 | 用于递送核酸的复合物 |
| TWI858802B (zh) * | 2022-07-06 | 2024-10-11 | 南韓商綠十字股份有限公司 | 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒 |
| CA3263437A1 (en) | 2022-07-29 | 2024-02-01 | Fujifilm Corporation | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE SIGNAL REGULATOR ALPHA PROTEIN (SIRPα) GENE |
| WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| WO2024057237A1 (en) | 2022-09-16 | 2024-03-21 | Pfizer Inc. | Lipid nanoparticles |
| EP4342460A1 (en) | 2022-09-21 | 2024-03-27 | NovoArc GmbH | Lipid nanoparticle with nucleic acid cargo |
| EP4637718A1 (en) * | 2022-12-21 | 2025-10-29 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticles comprising sterol-modified phospholipids |
| EP4642797A1 (en) | 2022-12-28 | 2025-11-05 | BioNTech SE | Rna compositions targeting hiv |
| EP4410316A1 (en) * | 2023-02-01 | 2024-08-07 | 4basebio UK Ltd | Nanoparticles for delivery of nucleic acid cargos |
| AU2024217077A1 (en) * | 2023-02-06 | 2025-09-18 | University Of Tennessee Research Foundation | Multi-functional lipid nanoparticles and uses thereof |
| WO2024205499A1 (en) * | 2023-03-27 | 2024-10-03 | Agency For Science, Technology And Research | A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof |
| WO2024259158A2 (en) * | 2023-06-13 | 2024-12-19 | Cornell University | Lipid nanoparticles for peptide delivery and methods of making and using the same |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| CN121866336A (zh) | 2023-08-03 | 2026-04-14 | 百欧恩泰欧洲股份公司 | 靶向hiv的rna组合物 |
| CN121752256A (zh) | 2023-09-01 | 2026-03-27 | 诺沃阿克有限责任公司 | 具有核酸负载物和可电离脂质的脂质纳米颗粒 |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025219570A1 (en) | 2024-04-17 | 2025-10-23 | Johannes Kepler Universität Linz | Composition for inhibiting protein translocation and methods using the same |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
| GB202408360D0 (en) | 2024-06-11 | 2024-07-24 | Cancer Research Tech Ltd | Tumour sensitisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3007955A1 (en) * | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| AU2017286980B2 (en) * | 2016-06-30 | 2023-10-26 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
-
2020
- 2020-04-24 MA MA055766A patent/MA55766A/fr unknown
- 2020-04-24 US US17/605,698 patent/US20220168222A1/en not_active Abandoned
- 2020-04-24 WO PCT/US2020/029907 patent/WO2020219941A1/en not_active Ceased
- 2020-04-24 CA CA3137450A patent/CA3137450A1/en active Pending
- 2020-04-24 JP JP2021562869A patent/JP2022530018A/ja not_active Abandoned
- 2020-04-24 EP EP20795521.2A patent/EP3959314A4/en not_active Withdrawn
- 2020-04-24 AU AU2020262437A patent/AU2020262437A1/en not_active Abandoned
- 2020-04-24 CN CN202080046391.4A patent/CN114026233A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114026233A (zh) | 2022-02-08 |
| US20220168222A1 (en) | 2022-06-02 |
| EP3959314A1 (en) | 2022-03-02 |
| WO2020219941A1 (en) | 2020-10-29 |
| EP3959314A4 (en) | 2023-02-08 |
| MA55766A (fr) | 2022-03-02 |
| AU2020262437A1 (en) | 2021-12-23 |
| JP2022530018A (ja) | 2022-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4262883B1 (en) | Peg lipids and lipid nanoparticles | |
| AU2020262437A1 (en) | Lipid nanoparticles | |
| US12357705B2 (en) | Negatively charged peg-lipid conjugates | |
| AU2019376161B2 (en) | Lipid nanoparticle formulations | |
| CA3118559A1 (en) | Lipid nanoparticle formulations | |
| US20110071208A1 (en) | Lipid encapsulated dicer-substrate interfering rna | |
| EP3877001A1 (en) | Cationic lipids containing silicon | |
| US20240065982A1 (en) | Lipid nanoparticles for delivering therapeutics to lungs | |
| EP4121018A2 (en) | Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells | |
| WO2023144792A1 (en) | Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same | |
| HK40094731A (en) | Peg lipids and lipid nanoparticles | |
| HK40094731B (en) | Peg lipids and lipid nanoparticles | |
| CA3119071C (en) | Lipid nanoparticle formulations | |
| WO2026022656A2 (en) | Lipid particle formulations with permanently charged cationic lipids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211026 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251009 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |